An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease

The aims were to determine the effect of an oral inhibitor of the signaling mediator p38 mitogen‐activated protein kinase (GW856553, losmapimod) on sputum neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic obstructive pulmonary disease (COPD). Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 μg/500 μg combination (SFC), or placebo in a 12‐week, randomized, double‐blind, double‐dummy study (MKI102428/NCT00642148). Neither losmapimod nor SFC had an effect on the primary end point of sputum neutrophils. Losmapimod was well tolerated and reduced plasma fibrinogen by 11% (−0.4 g/L, ratio of effect of losmapimod/placebo 0.89; 95% confidence interval, 0.83–0.96; P = .002) with nonsignificant reductions in interleukin‐6, interleukin‐8, and C‐reactive protein. There was evidence of improvement in hyperinflation with losmapimod compared with placebo (overall P = .02). Inhaled SFC significantly improved lung function and reduced serum CC‐16 (ratio of effect of SFC/placebo 0.87; 95% confidence interval, 0.82–0.93; P < .001). It was concluded that oral losmapimod significantly reduced plasma fibrinogen in patients with COPD.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  Dave Singh,et al.  A Randomized, Placebo‐Controlled Study of the Effects of the p38 MAPK Inhibitor SB‐681323 on Blood Biomarkers of Inflammation in COPD Patients , 2010, Journal of clinical pharmacology.

[3]  J. Maurer.  Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study , 2010 .

[4]  K. Chung,et al.  Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma , 2009, European Respiratory Journal.

[5]  I. Adcock,et al.  Glucocorticoid resistance in inflammatory diseases , 2009, The Lancet.

[6]  M. Genovese.  Inhibition of p38: has the fat lady sung? , 2009, Arthritis and rheumatism.

[7]  L. Edwards,et al.  Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD , 2009, European Respiratory Journal.

[8]  P. Nilsson,et al.  Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study , 2008, Thorax.

[9]  F. Karadağ,et al.  Biomarkers of Systemic Inflammation in Stable and Exacerbation Phases of COPD , 2008, Lung.

[10]  L. Edwards,et al.  Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort , 2008, Thorax.

[11]  D. Sin,et al.  The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[12]  S. Medicherla,et al.  p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation , 2008, Journal of Pharmacology and Experimental Therapeutics.

[13]  D. Postma,et al.  Increased systemic inflammation is a risk factor for COPD exacerbations. , 2008, Chest.

[14]  L. Fabbri,et al.  Increased activation of p38 MAPK in COPD , 2008, European Respiratory Journal.

[15]  L. Edwards,et al.  Evaluation of serum CC-16 as a biomarker for chronic obstructive pulmonary disease in the ECLIPSE cohort on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators , 2008 .

[16]  D. Sin,et al.  The Effects of Fluticasone With or Without Salmeterol On Systemic Biomarkers of Inflammation in COPD , 2008 .

[17]  Nigel S Dallow,et al.  Practical usage of O'Brien's OLS and GLS statistics in clinical trials , 2008, Pharmaceutical statistics.

[18]  E. Benjamin,et al.  Systemic inflammation and COPD: the Framingham Heart Study. , 2008, Chest.

[19]  S. Holgate,et al.  A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[20]  W. MacNee.  Pathogenesis of chronic obstructive pulmonary disease. , 2007, Clinics in chest medicine.

[21]  J. D’Armiento,et al.  Emerging role of MAP kinase pathways as therapeutic targets in COPD , 2006, International journal of chronic obstructive pulmonary disease.

[22]  I. Pavord,et al.  Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. , 2006, American journal of respiratory and critical care medicine.

[23]  J. Soriano,et al.  C-reactive protein in patients with COPD, control smokers and non-smokers , 2005, Thorax.

[24]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[25]  A. Agustí,et al.  COPD, a multicomponent disease: implications for management. , 2005, Respiratory medicine.

[26]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[27]  B. Nordestgaard,et al.  Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[28]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[29]  T. Seemungal,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.